Latest Breaking News On - Arthurf ryan - Page 5 : comparemela.com

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective hoisted by TD Cowen from $1,020.00 to $1,030.00 in a report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other analysts also recently commented on the stock. Truist Financial restated a buy rating […]

Andrewj murphyArthurf ryanSanfordc bernsteinNews ratings for regeneron pharmaceuticals dailyRegeneron pharmaceuticalsHedge funds weigh in on regeneron pharmaceuticalsAnnis gardner whiting capital advisorsRegeneron pharmaceuticals trading downAnalyst recommendations for regeneron pharmaceuticalsInsider transactions at regeneron pharmaceuticalsPaces advisors incFortitude family officeSecurities exchange commissionRegeneron pharmaceuticals incRoyal bankCriterion capital advisors